|
the wet blanket chimes in
Hi all,
I hope that this does turn out to be something. Vaccines have fascinated me for some time. (I was signed up for one of the Seattle/UW trials when GSK cancelled it). But if you read past the headlines, this study doesn't sound quite as rosy.
For one thing, this was an extremely small study, especially by the time they broke people down into the four groups.
For another thing, the average follow-up was only 3 years. How can they claim a mortality advantage, especially in HER2 negative women, in only 3 years? It does say, in one article of three that I read, that these results were not statistically significant. YES, FIFTY PERCENT REDUCTION, NO DEATHS. But oh, well, yeah, that was not statistically significant.
Plus, what the heck is that about a 38% mortality in the control group. Almost 40% of the HER2negative women DIED by three years!? It would be surprising to see that high a rate of recurrence, let alone death. There's got to be more to this story.
Skeptically, but with hope,
Debbie Laxague
|